Trimethoprim-Sulfamethoxazole Effects on the Nasal Microbiome in Granulomatosis with Polyangiitis Study

Recruiting
18 years - 99 years
All
Phase N/A
10 participants needed
1 Location

Brief description of study

Trimethoprim-sulfamethoxazole (TMP-SMX; Bactrim) is an FDA-approved drug for the treatment of infections and commonly used for 2 weeks or less. The purpose of this study is to observe the changes in the microbiome in your nose before, during, and after taking TMP-SMX for 4 weeks. The extended duration of TMP-SMX used in this study was selected to better understand what type of changes occurred in the microbes or your nose and also the effects on your immune system.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Granulomatosis With Polyangiitis | Wegener Granulomatosis; GPA
  • Age: 18 years - 99 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 831864

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.